Latest:
Dr. Diamond on the Need to Integrate MRD Testing Into Clinical Trials in Multiple Myeloma
Benjamin Diamond, MD, discusses the need to integrate minimal residual disease testing into clinical trials in multiple myeloma.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Meredith McKean, MD, MPH
Latest:
Darovasertib Plus Crizotinib in First-Line Metastatic Uveal Melanoma: Phase 1/2 OptimUM-01 Results
The presentation highlights results from the OptimUM-01 study evaluating
darovasertib + crizotinib as first-line treatment for metastatic uveal melanoma, showing
improved median overall survival (21.1 months) and higher response rates compared with
historical standard therapies. The combination demonstrated a manageable safety profile,
supporting its continued evaluation in the ongoing registrational OptimUM-02 trial.
Sandra L. Starnes, MD
Latest:
Women in Oncology: Self-Advocacy in a Busy Field
Melinda Butsch Kovacic, MPH, PhD; Elizabeth Shaughnessy, MD, PhD; Sandra L. Starnes, MD; and Susan E. Waltz, PhD, discuss the advice they would give to their younger selves and future female oncology professionals, knowing what they know now about the oncology field and their own career growth.
Melinda Weber, DNP, RN, APN, AOCN, C.
Latest:
Comorbidities, Quality of Life, Efficacy, and Safety in Expanding Subcutaneous Treatment Use
Panelists discuss how subcutaneous checkpoint inhibitors are appropriate for nearly all patients except those with severe cachexia limiting injection sites, with patient conversations emphasizing equivalent efficacy data, safety profiles, quality of life benefits including potential home administration, and the option to maintain IV therapy for patients who prefer their current regimen.
Jason Fangusaro, MD
Latest:
Potential Adverse Events With Targeted Therapies
The panel of pediatric low-grade glioma (pLGG) experts delves into the potential adverse events associated with targeted therapies, outlining common reactions and their severity, while also sharing their strategies and best practices for toxicity management.
Gregory J. Tiesi, MD, FACS, FSSO
Gregory J. Tiesi, MD, FACS, FSSO, is the medical director of Hepatobiliary Surgery at the Hackensack Meridian Jersey Shore University Medical Center
Latest:
Hepatic Artery Infusion Refines Liver-Directed Care for GI Cancers: With Gregory J. Tiesi, MD, FACS, FSSO; Anthony Scholer, MD, FACS, FSSO; Benjamin Jon Golas, MD, FACS; and Eric Pletcher, MD
Drs Tiesi, Scholer, Golas, and Pletcher discuss the use of hepatic artery infusion in colon cancer and liver cancer management.
Cindy Varga, MD
Latest:
Dr. Varga on Current Clinical Trials for Patients with Relapsed/Refractory Multiple Myeloma
Cindy Varga, MD, discusses several exciting clinical trials at the Levine Cancer Institute for patients with relapsed/refractory multiple myeloma with acquired resistance to BCMA-directed therapy.
Johannes Schetelig, MD, MSc
Johannes Schetelig, MD, MSc, is director of medical research at Deutsche Knochenmarkspenderdatei; as well as a professor at Technical University Dresden
Latest:
Dr Schetelig on Challenges Assessing Haploidentical vs Mismatched Transplantation in AML/ALL/MDS
Johannes Schetelig, MD, discusses challenges with assessing haploidentical related vs mismatched unrelated donor transplantation in high-risk AML/ALL/MDS